New inhaled migraine treatment shows promise in early trial
NCT ID NCT07226362
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a new inhaled powder form of the migraine drug dihydroergotamine (DHE) in 44 healthy adults. Researchers compared how the body absorbs the drug when inhaled versus when given as a nasal spray or injection. The goal was to check safety and measure drug levels, not to treat migraines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dihydroergotamine mesylate (DHE)
- What this could lead to
- If successful, this could lead to a new, easier-to-use inhaled form of DHE for migraine attacks.
- What could go wrong
- This is an early Phase 1 study in healthy people, not migraine patients. It only checks safety and how the drug moves in the body, not if it works for migraines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY, AND TOLERABILITY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alliance for Multispecialty research (AMR)
Knoxville, Tennessee, 37920, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New heartburn drug candidate tested for heart safety in healthy volunteers
- Experimental kidney drug DF-003 enters first human safety trial
- New antibody AK1967 tested in healthy men as potential shock therapy
- 12 healthy volunteers test drug combo in Early-Stage study
- New obesity drug MKP10241 enters human testing – food may change how it works